Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Explore Regeneron Pharmaceuticals analyst ratings and price targets (NASDAQ:REGN) on Benzinga. Stay updated on expert opinions and forecasts for REGN stock.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

Investing.com - UBS raised its price target on Regeneron Pharmaceuticals (NASDAQ: REGN) to $584.00 from $560.00 while maintaining a Neutral rating on the stock.According to InvestingPro data ...

On Friday, Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on ...

This was the stock's fourth consecutive day of gains.

On Friday, RBC Capital Markets downgraded Regeneron (NASDAQ: REGN) Pharmaceuticals’ shares, moving the rating from Outperform to Sector Perform.The firm also significantly reduced the price ...

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. The Significance of Analyst Ratings Explained ...